Free Trial

ABVC BioPharma (ABVC) Competitors

ABVC BioPharma logo
$2.96 -0.08 (-2.63%)
Closing price 10/13/2025 04:00 PM Eastern
Extended Trading
$2.98 +0.02 (+0.84%)
As of 10/13/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ABVC vs. NMRA, ALLO, JBIO, TNYA, VTYX, SOPH, TKNO, TECX, ABEO, and AVTE

Should you be buying ABVC BioPharma stock or one of its competitors? The main competitors of ABVC BioPharma include Neumora Therapeutics (NMRA), Allogene Therapeutics (ALLO), Jade Biosciences (JBIO), Tenaya Therapeutics (TNYA), Ventyx Biosciences (VTYX), SOPHiA GENETICS (SOPH), Alpha Teknova (TKNO), Tectonic Therapeutic (TECX), Abeona Therapeutics (ABEO), and Aerovate Therapeutics (AVTE). These companies are all part of the "pharmaceutical products" industry.

ABVC BioPharma vs. Its Competitors

ABVC BioPharma (NASDAQ:ABVC) and Neumora Therapeutics (NASDAQ:NMRA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, analyst recommendations, earnings, media sentiment and risk.

ABVC BioPharma has a beta of 0.3, meaning that its share price is 70% less volatile than the S&P 500. Comparatively, Neumora Therapeutics has a beta of 2.92, meaning that its share price is 192% more volatile than the S&P 500.

ABVC BioPharma has higher revenue and earnings than Neumora Therapeutics. ABVC BioPharma is trading at a lower price-to-earnings ratio than Neumora Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ABVC BioPharma$510K136.62-$4.90M-$0.17-17.41
Neumora TherapeuticsN/AN/A-$243.79M-$1.57-1.18

ABVC BioPharma's return on equity of -46.76% beat Neumora Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
ABVC BioPharmaN/A -46.76% -23.02%
Neumora Therapeutics N/A -98.95%-87.68%

In the previous week, ABVC BioPharma and ABVC BioPharma both had 3 articles in the media. ABVC BioPharma's average media sentiment score of 0.83 beat Neumora Therapeutics' score of 0.83 indicating that ABVC BioPharma is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
ABVC BioPharma
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Neumora Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

11.4% of ABVC BioPharma shares are held by institutional investors. Comparatively, 47.7% of Neumora Therapeutics shares are held by institutional investors. 17.1% of ABVC BioPharma shares are held by insiders. Comparatively, 26.8% of Neumora Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Neumora Therapeutics has a consensus target price of $7.14, suggesting a potential upside of 284.02%. Given Neumora Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Neumora Therapeutics is more favorable than ABVC BioPharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ABVC BioPharma
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Neumora Therapeutics
3 Sell rating(s)
4 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.00

Summary

Neumora Therapeutics beats ABVC BioPharma on 7 of the 13 factors compared between the two stocks.

Get ABVC BioPharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for ABVC and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ABVC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ABVC vs. The Competition

MetricABVC BioPharmaMED IndustryMedical SectorNASDAQ Exchange
Market Cap$71.57M$3.36B$6.05B$10.30B
Dividend YieldN/A2.31%5.73%4.82%
P/E Ratio-17.4122.0885.3127.10
Price / Sales136.62478.69601.46133.24
Price / CashN/A44.9825.7730.18
Price / Book49.3310.3812.676.69
Net Income-$4.90M-$52.47M$3.32B$276.55M
7 Day Performance-8.07%0.18%-0.05%-0.40%
1 Month Performance3.86%13.95%8.73%6.53%
1 Year Performance491.88%20.83%78.85%41.04%

ABVC BioPharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ABVC
ABVC BioPharma
0.8514 of 5 stars
$2.96
-2.6%
N/A+527.1%$71.57M$510K-17.4130
NMRA
Neumora Therapeutics
2.11 of 5 stars
$1.86
-1.6%
$7.14
+284.0%
-88.0%$301.23MN/A-1.18108
ALLO
Allogene Therapeutics
2.5564 of 5 stars
$1.35
-2.2%
$8.44
+525.5%
-52.1%$299.54MN/A-1.22310Analyst Downgrade
Gap Up
JBIO
Jade Biosciences
2.5018 of 5 stars
$9.04
-1.1%
$16.00
+77.0%
N/A$294.98MN/A-0.3020Gap Down
High Trading Volume
TNYA
Tenaya Therapeutics
2.9901 of 5 stars
$1.77
+2.9%
$6.25
+253.1%
+11.9%$288.48MN/A-1.84110Gap Up
VTYX
Ventyx Biosciences
1.9145 of 5 stars
$3.98
+6.7%
$7.50
+88.4%
+73.4%$283.81MN/A-2.3730
SOPH
SOPHiA GENETICS
2.2666 of 5 stars
$4.16
+2.7%
$8.00
+92.3%
+15.1%$281.13M$65.17M-9.45520
TKNO
Alpha Teknova
2.0662 of 5 stars
$5.24
-7.3%
$10.00
+90.8%
-8.1%$280.39M$37.74M-12.48240
TECX
Tectonic Therapeutic
2.7938 of 5 stars
$14.91
-1.9%
$80.29
+438.5%
-48.7%$278.97MN/A-3.69120
ABEO
Abeona Therapeutics
4.3851 of 5 stars
$5.25
-1.7%
$19.50
+271.4%
-15.6%$269.22M$400K7.5090News Coverage
Analyst Forecast
Gap Up
AVTE
Aerovate Therapeutics
N/A$9.14
+3.2%
N/A-87.8%$264.92MN/A-3.0620High Trading Volume

Related Companies and Tools


This page (NASDAQ:ABVC) was last updated on 10/14/2025 by MarketBeat.com Staff
From Our Partners